95% CI for hazard ratio (HR) | ||||
---|---|---|---|---|
HR | Lower | Upper | P-value | |
HF-phenotypes | < 0.001 | |||
HFpEF | Reference | |||
HFmrEF | 0.95 | 0.77 | 1.18 | |
HFrEF | 1.12 | 0.91 | 1.38 | |
HFndEF | 1.49 | 1.27 | 1.74 | |
Gender | ||||
Women, n (%)1 | 0.90 | 0.80 | 1.02 | 0.10 |
Age (continous variable) | 1.04 | 1.03 | 1.06 | < 0.001 |
Comorbidities | ||||
Hypertension | 0.91 | 0.79 | 1.06 | 0.22 |
Cardiovascular disease | 0.98 | 0.87 | 1.11 | 0.78 |
Atrial fibrillation, n (%) | 1.06 | 0.93 | 1.20 | 0.38 |
Diabetes, n (%) | 1.31 | 1.13 | 1.52 | < 0.001 |
COPD, n (%) | 1.51 | 1.29 | 1.77 | < 0.001 |
Kidney function | < 0.001 | |||
> 60 ml/min, n (%) | Reference | |||
30–60 ml/min, n (%) | 1.00 | 0.86 | 1.15 | |
< 30 ml/min, n (%) | 1.88 | 1.56 | 2.28 | |
NT-proBNP levels | < 0.001 | |||
HF unlikely, n (%) | Reference | |||
Grey zone, n (%) | 1.31 | 0.99 | 1.73 | |
HF likely, n (%) | 2.09 | 1.59 | 2.76 | |
Pharmacotherapy | ||||
Betablockers and RAASi | 0.52 | 0.44 | 0.61 | < 0.001 |
Healthcare utilization | ||||
Inpatient care (days) | 1.02 | 1.01 | 1.02 | < 0.001 |
Hospital admissions | 1.21 | 1.17 | 1.25 | < 0.001 |
Outpatient care visits | 0.96 | 0.95 | 0.98 | < 0.001 |
Visit to primary care physician | 0.16 | 0.14 | 0.19 | < 0.001 |